Connecting Underrepresented Populations to Clinical Trials (CUSP2CT)
The Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) program will implement and evaluate multilevel and culturally tailored outreach and education interventions with the primary goal of increasing referral and ultimately, accrual of underrepresented racial/ethnic (R/E) minority populations, to NCI-supported clinical trials (CTs) (National Clinical Trial Network (NCTN), NCI's Community Oncology Research Program (NCORP), and Experimental Therapeutics Clinical Trials Network (ETCTN)). These programs’ target population(s) will include individuals from underrepresented racial/ethnic minority populations and will address cancer health disparities through a network of local multidisciplinary and integrated partners.
Without adequate representation, especially in therapeutic trials, cancer disparities are likely to increase as R/E populations may not be able to fully benefit from cutting-edge treatments and the promises of precision medicine.
CUSP2CT is comprised of two Funding Opportunity Announcements. This program is not accepting new applications.
|
Title |
Purpose |
|---|---|
|
The DECC is intended to support CUSP2CT, a program designed to increase referral to NCI-supported clinical trials (CTs) among underrepresented racial/ethnic (R/E) minority populations who experience disproportionately higher rates of incidence, morbidity, and mortality for numerous cancer types in comparison to Non-Hispanic Whites (NHW). Awardee: Mayo Clinic Rochester |
|
|
CUSP2CT will implement and evaluate multilevel and culturally tailored outreach and education interventions with the primary goal of increasing referral and ultimately, accrual of underrepresented racial/ethnic (R/E) minority populations, to NCI-supported clinical trials (CTs). Awardees:
|